Skip to content

Study to see the role of Kala Vasti of Rasnadashmoolakam and Saidhvadya Taila Brhat in Amavata (Rheumatoid Arthritis)

Study to evaluate the efficacy of kala vasti [Rasnadashmoolakam and saindhvadya taila brhat] in Amavata (Rheumatoid arthritis)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/07/015081
Enrollment
40
Registered
2018-07-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patient suffering from disease since at least 3 years diagnosed according to clinical features of amavata described in madhava nidana patient should full fill the 2010 ACR-EULAR criteria Health Condition 2: M059- Rheumatoid arthritis with rheumatoid factor, unspecified Health Condition 3: M059- Rheumatoid arthritis with rheumatoid factor, unspecified Health Condition 4: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: rasnadashmoolakam and sandhvadya taila brhat: in the form of vasti anuvasana vasti with sandhvadya taila brhat dose 60ml and niruha vasti with rasnadashmoolakam dose 480ml in the form o

Sponsors

Dept of Kayachikitsa Chaudhary Brham Prakash Ayurved Charak Sansthan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patient suffering from disease since atleast 3 years Amavata will be diagnosed according to the clinical features described in Madhav nidan patient should fulfill the 2010 ACR EULAR criteria

Exclusion criteria

Exclusion criteria: Patient Having severe crippling bone deformities Patient suffering from paralysis or any type of arthropathy such as neoplasm of spine Gout Ankylosing spondylitis Traumatic arthritis Pyogenic osteomyelitis Patients having associated Cardiac disease tuberculosis malignant Hypertension Impairement of Liver function and Renal Functions Malignancy HIV AIDS Pregnant women and lactating mother

Design outcomes

Primary

MeasureTime frame
Reduction in pain ACR EULAR criteria DAS28 Ritchie articular index RA Factor ESR CRPTimepoint: Reduction in pain ACR EULAR criteria DAS28 Ritchie articular index RA Factor ESR CRP on 16th day and 48th day

Secondary

MeasureTime frame
noneTimepoint: none

Countries

India

Contacts

Public ContactDr Alka Narnolia

Chaudhary Brham Prakash Ayurved Charak Sansthan

naimishraj@yahoo.com9560659728

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026